Markets:

Overview

News

Currencies

International

Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

1.690 +0.020 (+1.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday ↗

January 03, 2025

Via Benzinga

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

January 02, 2025

From DJS Law Group

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 02, 2025

Via Benzinga

Crude Oil Surges 2%; Tesla Shares Plummet ↗

January 02, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Nasdaq Dips Over 100 Points; Unity Software Shares Jump ↗

January 02, 2025

Via Benzinga

Dow Surges Over 300 Points; US Initial Jobless Claims Decline ↗

January 02, 2025

Via Benzinga

Topics Stocks

Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops ↗

January 02, 2025

The company said it plans to investigate a positive signal from female patients.

Via Investor's Business Daily

Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 02, 2025

Via Benzinga

Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials ↗

January 02, 2025

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated.

Via Benzinga

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

January 02, 2025

From Neumora Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 18, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in November

November 06, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 05, 2024

Via Benzinga

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

October 29, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 21, 2024

Via Benzinga

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

August 14, 2024

Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET

From Neumora Therapeutics, Inc.

Via GlobeNewswire

NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 ↗

August 06, 2024

NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 06, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation

June 20, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

May 14, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 ↗

May 07, 2024

NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 07, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in May

May 06, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March ↗

April 15, 2024

U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 15, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...

Via Benzinga

Crude Oil Down 1%; Charles Schwab Sales Top Estimates ↗

April 15, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...

Via Benzinga

Topics Stocks

Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? ↗

April 15, 2024

Neumora Therapeutics faces setbacks as FDA halts Phase 1 trial of NMRA-266 due to convulsion concerns in rabbits. Phase 1 study paused; company working with FDA for resolution.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

All News about Neumora Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today